Smart scans and DNA tests could tailor lymphoma therapy, reducing chemo for some

NCT ID NCT06050694

Recruiting now Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new way to treat diffuse large B-cell lymphoma (DLBCL) by using PET scans and blood DNA tests early in treatment to decide the best next steps. About 40 adults with untreated DLBCL will start standard chemo, then get either shorter chemo if tests show low risk, or a new drug (glofitamab) if high risk. The goal is to see if this personalized approach is feasible and safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Jewish General Hospital
RECRUITING

Montreal, Quebec, H3T 1E2, Canada
Princess Margaret Cancer Centre
NOT_YET_RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.